Limit search to available items
Book Cover

Title Indacaterol : the first once-daily long-acting Beta2 Agonist for COPD / Alexandre Trifilieff, editor
Published Basel : Springer, 2014


Description 1 online resource (vii, 146 pages) : illustrations (some color)
Series Milestones in Drug Therapy, 2296-6056
Milestones in drug therapy, 2296-6056
Contents Current Pharmacotherapy for COPD / James F. Donohue, Matthew C. Miles and Jill A. Ohar -- The Preclinical Pharmacology of Indacaterol / Alexandre Trifilieff, Steven J. Charlton and Robin A. Fairhurst -- The Design of the Indacaterol Molecule / Robin A. Fairhurst, Steven J. Charlton and Alexandre Trifilieff -- The Early Clinical Development of Indacaterol / Jutta Beier and Kai M. Beeh -- INHANCE: An Adaptive Confirmatory Study with Dose Selection at Interim / David Lawrence, Frank Bretz and Stuart Pocock -- Phase 3 Clinical Efficacy Studies: Lung Function / Ronald Dahl -- Phase III Clinical Efficacy of Indacaterol: Patient-Centered Outcomes / Donald A. Mahler -- The History and Performance of the Breezhaler Device / David Young, Lee Wood, Dilraj Singh and Juergen Dederichs -- What Does the Future Hold for the Therapy of COPD? / Peter J. Barnes
Current Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies: lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD?
Summary Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD
Bibliography Includes bibliographical references
Notes English
Online resource; title from PDF title page (SpringerLink, viewed November 18, 2013)
In Springer eBooks
Subject Lungs -- Diseases, Obstructive -- Treatment
Adrenergic beta agonists.
Pulmonary Disease, Chronic Obstructive -- drug therapy
Indans -- pharmacokinetics
Quinolones -- pharmacokinetics
Adrenergic beta-2 Receptor Agonists
Clinical Trials as Topic
Nebulizers and Vaporizers
Adrenergic beta-Agonists
HEALTH & FITNESS -- Diseases -- General.
MEDICAL -- Clinical Medicine.
MEDICAL -- Diseases.
MEDICAL -- Evidence-Based Medicine.
MEDICAL -- Internal Medicine.
Adrenergic beta agonists.
Lungs -- Diseases, Obstructive -- Treatment.
Form Electronic book
Author Trifilieff, Alexandre, editor
ISBN 9783034807098